Radionuclide-Based Therapy for Metastatic Castration-Resistant Prostate Cancer: Multidisciplinary Considerations

Join Daniel P. Petrylak, MD, and Chaitanya R. Divgi, MD, for an informative multidisciplinary discussion of best practices and the supporting evidence for the clinical use of the new radionuclide therapy for patients with metastatic castration-resistant prostate cancer.

Interactive Virtual Presentation

In this downloadable slideset, Daniel P. Petrylak, MD, and Chaitanya R. Divgi, MD, MBBS, examine best practices and the supporting evidence for the clinical use of the new radionuclide therapy for patients with metastatic castration-resistant prostate cancer.

Released: February 7, 2014
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by Bayer Healthcare along with Algeta US
Bayer Healthcare along with Algeta US

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?